Pharmacological treatment of acute heart failure: current treatment and new targets (Q38122297)

29 August 2017

title

Pharmacological treatment of acute heart failure: current treatment and new targets (English)

1 reference

acute decompensated heart failure

29 August 2017

0 references

1 reference

J Pöss

1

1 reference

29 August 2017

A Link

series ordinal

2

1 reference

29 August 2017

M Böhm

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 October 2013

1 reference

Clinical Pharmacology & Therapeutics

29 August 2017

published in

1 reference

29 August 2017

volume

94

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

499-508

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

29 August 2017

1 reference

The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Intracardiac fistula due to prosthetic aortic valve abscess causing acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Experience with revascularization procedures does matter: low volume means worse outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Practical applications of intravenous diuretic therapy in decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Diuretic Strategies in Patients with Acute Decompensated Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Combination diuretic treatment in severe heart failure: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

The role of the kidney in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effect of nesiritide in patients with acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Levosimendan, a novel Ca2 sensitizer, activates the glibenclamide-sensitive K channel in rat arterial myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Adenosine and kidney function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Adenosine and kidney function: potential implications in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Novel pharmacologic therapies in development for acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Maternal vasodilation in pregnancy: the emerging role of relaxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

The renal urodilatin system: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Renal effects of ularitide in patients with decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Acute heart failure: lessons learned so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

Why do drugs for acute heart failure fail?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

7 January 2021

Cardiogenic shock due to dynamic left ventricular outflow tract obstruction in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

7 January 2021

The perindopril in elderly people with chronic heart failure (PEP-CHF) study

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

7 January 2021

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

7 January 2021

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

7 January 2021

Dopamine depresses minute ventilation in patients with heart failure

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

7 January 2021

Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

7 January 2021

Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

7 January 2021

Haemodynamic and clinical effects of ularitide in decompensated heart failure

1 reference

https://api.crossref.org/works/10.1038/CLPT.2013.136

7 January 2021

Identifiers

DOI

10.1038/CLPT.2013.136

1 reference

29 August 2017

1 reference